Roche's Enicepatide Posts 15.5% Weight Loss and Deep HbA1c Cuts in Phase 2 Diabetes Trial

What Happened

Roche has announced positive Phase 2 results for enicepatide (CT-388), its once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes and overweight or obesity. In the 48-week randomized, double-blind trial (447 participants), the highest dose tested delivered a mean HbA1c reduction of 2.65% from a baseline of 8.1%, alongside mean weight loss of 15.5% — with no evidence of a weight-loss plateau by week 48.

The glycemic numbers were the headline. 90% of patients in the highest-dose cohort reached an HbA1c at or below 6.5%, and 62% achieved normoglycemia (HbA1c below 5.7%), effectively restoring blood glucose to a non-diabetic range. Among patients who started with poor control (HbA1c above 8.5%), the reduction reached 4.13%.

Safety was consistent with the incretin class — predominantly mild-to-moderate gastrointestinal effects — with discontinuation due to adverse events at 2.0% in treatment arms versus 0.0% on placebo.

Who Is Affected

• Adults with type 2 diabetes and obesity, who stand to gain a third major incretin competitor alongside Eli Lilly's and Novo Nordisk's portfolios
• The obesity-drug market, where Roche is positioning enicepatide as a potential best-in-disease agent
• Researchers tracking incretin pharmacology, especially dual-agonist and biased-agonist design
• Gray-market suppliers of research-grade GLP-1 compounds, whose demand story weakens as approved alternatives multiply

Timeline

• 2023 — Roche acquires Carmot Therapeutics, bringing CT-388 into its cardiometabolic pipeline
• January 2026 — Phase 2 obesity data show 22.5% placebo-adjusted weight loss; the program moves toward pivotal trials
• June 2026 — Further obesity-portfolio data presented at a major diabetes conference
• September 22, 2026 — Phase 2 diabetes topline announced; Roche confirms two ongoing Phase 3 weight-management studies (ENITH-1 and ENITH-2)
• First half of 2027 — Planned initiation of a Phase 3 glycemic-control program and cardiovascular outcomes trials

What This Means for Researchers

Two things stand out. First, the 62% normoglycemia rate at 48 weeks is a strong benchmark for a dual GLP-1/GIP agent in a type 2 diabetes population — a direct challenge to the incumbent dual agonist, tirzepatide, and a step beyond what GLP-1-only agents have shown in comparable populations. Second, enicepatide is a biased agonist, engineered to signal preferentially through the Gs-protein pathway at both receptors; whether that design translates into differentiated clinical outcomes is precisely what the Phase 3 program will test.

For the research-compound market, the signal is simpler: every successful late-stage incretin adds pressure on the compounded and research-grade supply chain, because demand migrates toward approved products as the approved field gets more crowded.

How to Verify Your Peptides

Pipeline news does not change supplier quality. If you purchase GLP-1 compounds for research:

• Require a batch-specific certificate of analysis for every order
• Verify identity and purity independently — our testing methodology guide covers the standard workflow
• For these molecules, see our semaglutide purity testing and tirzepatide HPLC testing references

Safe Alternatives

Approved incretin therapies remain the evidence-backed option for clinical use. Compare research compound profiles in our peptide database — including semaglutide and tirzepatide — and use our vetted vendor directory when sourcing materials.

Sources

Company regulatory disclosures and industry reports.